I placebokontrollerade kliniska prövningar var den totala förekomsten av maligniteter (varav de flesta var hudcancer, dock inte melanom) likartad bland patienter behandlade med Raptiva och placebobehandlade patienter. ###>In placebo controlled clinical trials, the overall incidences of malignancy (the majority of which were non-melanoma skin cancers) were similar in Raptiva-treated patients and in placebo-treated patients.